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We had previously demonstrated the anti-diabetic potential and pancreatic protection
of two thiazolidin-4-one derivatives containing nicotinamide moiety (NAT-1 and NAT-2)
in STZ-induced diabetic mice. However, due to the limitations of the STZ model, we
decided to undertake a detailed evaluation of anti-diabetic potential of the molecules on
a high sucrose diet (HSD) fed diabetic mouse model. Further, in vitro mechanistic studies
on the phosphorylation of AMPK, Akt and p38 MAP kinase in L6 myotubes and anti-
inflammatory studies in RAW264.7 mouse monocyte macrophage cells were performed.
15 months of HSD induced fasting hyperglycaemia and impaired glucose tolerance in
mice. Treatment with NAT-1 and NAT-2 (100 mg/kg) for 45 days significantly improved
the glucose tolerance and lowered fasting blood glucose levels compared to untreated
control. An improvement in the elevated triglycerides and total cholesterol levels, and
favorable rise in HDL cholesterol were also observed with test drug treatment. Also, no
major changes were observed in the liver (albumin, AST and ALT) and kidney (creatinine
and urea) parameters. This was further confirmed in their respective histology profiles
which revealed no gross morphological changes. In L6 cells, significant phosphorylation
of Akt and p38 MAP kinase proteins were observed with 100 µM of NAT-1 and NAT-2
with no significant changes in phosphorylation of AMPK. The molecules failed to exhibit
anti-inflammatory activity as observed by their effect on the generation of ROS and
nitrite, and nuclear levels of NF-κB in LPS-stimulated RAW264.7 cells. In summary, the
molecules activated Akt and p38 MAP kinase which could have partly contributed to
their anti-hyperglycaemic and hypolipidemic activities in vivo.
Keywords: thiazolidin-4-one derivatives, high sucrose diet, mouse model, AMPK, Akt, p38 MAP kinase
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INTRODUCTION
We had previously reported pancreatic islet cell protection in
streptozotocin (STZ)-induced diabetic mice by two nicotinic
acid derivatives of thiazolidin-4-ones (designated NAT-1 and
NAT-2; Kishore et al., 2009). The molecules had exhibited anti-
hyperglycaemic and hypolipidemic activities in animal models
of diabetes and hyperlipidaemia, and reversed the damage to the
islets induced by streptozotocin (Joy et al., 2005; Nampurath et al.,
2008; Kishore et al., 2009). Though the STZ model of diabetes in
rodents, induced by destruction of islets of pancreas (Szkudelski,
2001; Chatzigeorgiou et al., 2009), is a widely reported, fast,
easy, and convenient method to evaluate anti-hyperglycaemic
activities of test compounds, the etiology of human type-II
diabetes mellitus (T2DM) seldom resembles this acute preclinical
model. Most cases of human T2DM involves chronic insulin
resistance, hyperinsulinemia, dyslipidemia, and hyperglycaemia
that eventually lead to pancreatic dysfunction (Defronzo and
Ferrannini, 1991). These conditions usually arise out of an
interplay between genetic and environmental factors with lifestyle
and food habits assuming important roles. So it was decided to
test the molecules on a model of diabetes induced by chronic
feeding of diet containing higher proportions of sugars and
fats (Sumiyoshi et al., 2006). In the current study, the effect of
the molecules were evaluated in mice rendered pre-diabetic by
feeding a diet containing high sucrose (55%) for a duration of
15 months.
In our previous studies, it was observed that the anti-
hyperglycaemic activities of the molecules were in part due to
their ability to enhance glucose uptake possibly through the
modulation of glucose metabolic pathway. Akt, AMPK, and p38
MAP kinase are key components of the metabolic pathways
that modulate glucose uptake independent of one another. The
binding of insulin to its receptor leads to the phosphorylation
of Akt. This eventually facilitates the translocation of GLUT4
transporters to the cell membrane leading to the uptake of
glucose in cells (Kohn et al., 1996; Manning and Cantley, 2007).
Phosphorylated Akt also modulates glycogen synthase kinase
(GSK-3) that exerts control over glucose metabolism (Cross
et al., 1995). AMPK, a cellular fuel gauge activated in response
to metabolic stress like energy starvation resulting in higher
AMP/ATP ratios, plays important roles in lipid and glucose
homeostasis. Phosphorylation of AMPK, through non-insulin
dependent pathways, also triggers GLUT4 translocation and
glucose uptake in skeletal muscle and adipocytes, increased fatty
acid oxidation and decreased fatty acid synthesis in liver and
skeletal muscles improving insulin sensitivity. It also decreases
cholesterol synthesis and gluconeogenesis in liver (Carling,
2004; Towler and Hardie, 2007; Zhang et al., 2009). The p38
mitogen activated protein kinase (p38 MAP kinase), a stress-
activated serine/threonine protein kinase which is activated by
a wide variety of chemicals including insulin, stimulates glucose
uptake independent of AMPK and Akt pathway. It also controls
inflammation and biosynthesis of proinflammatory cytokines like
IL-1 and TNF-α that play an important role in the development
of insulin resistance (Chambers et al., 2009; Kim and Choi, 2010).
Therefore, in vitro investigations were carried out to evaluate the
effect of the molecules on a few key components of the metabolic
pathways like AMPK, Akt, and p38 MAP kinase in L6 myotubes.
Inflammation plays an important role in the development of
diabetes. Chronic inflammation originating in adipose tissues
under conditions of hyperlipidaemia causes increased infiltration
of macrophages. Chronic activation of these macrophages and
their subsequent release of adipo-cytokines like TNF-α, IL-6, IL-
1 and activation of NF-κB eventually cause insulin resistance
in skeletal muscles (Xu et al., 2003; Kristiansen and Mandrup-
Poulsen, 2005; Nieto-Vazquez et al., 2008). Since the mechanism
of islet destruction by STZ is partly due to inflammation, and
as our molecules had previously shown partial reversal of islet
damage, it was also decided to evaluate the anti-inflammatory
activities of the molecules, by evaluating their effect on nitric
oxide (NO) and reactive oxygen species (ROS) production and
NF-κB levels in lipopolysaccharide (LPS) treated RAW264.7
(mouse monocyte macrophages) cells.
In the current study, both test molecules, NAT-1 and NAT-
2, were able to improve the glucose tolerance in 15 months
HSD-fed mice. In addition, no major liver or kidney toxicities
were observed due to treatments. NAT-2 showed increased
phosphorylation of Akt in L6 cells suggesting a possible role in
Akt-mediated glucose uptake.
MATERIALS AND METHODS
Chemicals
The molecules NAT-1 and NAT-2 (Figure 1) were synthesized,
purified and characterized as explained previously (Kishore
et al., 2009). Fetal bovine serum (GibcoTM) was purchased from
Thermo Fisher Scientific Inc. (Waltham, MA, USA). Casein,
cellulose, methionine, Dulbecco’s Modified Eagle Medium
(DMEM), penicillin–streptomycin, and trypsin–EDTA were
purchased from HiMedia Laboratories (Mumbai, Maharashtra,
India). Primary antibodies of AMPKα, Phospho-AMPKα
(Thr172), Akt, Phospho-Akt (Ser473), p38 MAP kinase (MAPK),
Phospho-p38 MAPK (Thr180/Tyr182), Phospho NF-kB were
purchased from Cell Signaling Technology (Danvers, MA,
USA). Cholesterol, choline bitartrate were procured from
Sigma-Aldrich Co. LLC (St. Louis, MO, USA). Normal pellet
diet for the animals were purchased from Amrit Feeds Ltd,
Pune, Maharashtra, India. Sugar (Madhur brand) manufactured
by Shree Renuka Sugars Ltd (Belgaum, Karnataka, India) was
procured from the local market. The kits for biochemical
estimations like triglycerides, total cholesterol, HDL cholesterol
were purchased from Rapid Diagnostic Pvt. Ltd (Aspen Kits, New
Delhi, India), and kits for the estimation of AST, ALT, albumin,
creatinine and urea were purchased from Roche Diagnostics Ltd
(Basel, Switzerland).
Animals and Treatment
The studies on whole animals and animal tissue samples
were conducted after obtaining clearance from the Institutional
Animal Ethics Committee, Kasturba Medical College, Manipal
University (approval no. IAEC/KMC/72/2012).
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FIGURE 1 | The chemical structure of the test compounds. (A) NAT-1:
N-[2-(4-Methoxy-phenyl)-4-oxo-thiazolidin-3-yl]-nicotinamide; (B) NAT-2:
N-[2-(3,5-Di-tert-butyl-4-hydroxy-phenyl)-4-oxo-thiazolidin-3-yl]-nicotinamide.
Male Swiss albino mice aged 3–4 weeks old and weighing
15–20 g were used for the study. The animals were maintained
in polypropylene cages in the Central Animal Research Facility
of Manipal University, with controlled temperature and 12 h
light–dark cycle. Four animals were housed per cage, and
maintained on high sucrose diet (HSD) (containing normal
pellet diet 28.1%, Sucrose 55%, Casein 8%, Cellulose 5%, Fats
3%, Methionine 0.5%, Choline bitartrate 0.25%, Mineral mix
0.15%) and water ad libitum for 15 months. Another group of
mice (n = 6) were fed normal pellet diet that served as normal
control.
At the end of 15 months, the HSD-fed mice were anesthetized
using isoflurane (Forane R©, Abbott House, Berkshire, UK) and
0.5 ml of blood was withdrawn retro-orbitally using micro
haematocrit tubes (Brand GMBH + CO KG, Wertheim,
Germany) in a 1.5 ml micro-centrifuge tube (Tarsons Products
Pvt. Ltd, Kolkata, West Bengal, India) containing dipotassium
EDTA (2 mg/ml of blood). Plasma was separated by centrifuging
(Micro 22R, Andreas Hettich GmbH & Co. KG, Tuttlingen,
Germany) at 6,000 rpm for 5 min at 25◦C. The plasma glucose
levels were estimated and only those animals with fasting plasma
glucose of 120–200 mg/dl (pre-diabetic) were included in the
study.
The pre-diabetic animals were randomized into four groups,
three treatment groups and one control group (n = 5–6), with
the same mean blood glucose.
Test compounds, NAT 1 and NAT-2, were prepared as
suspensions in 0.3% carboxy-methyl cellulose (CMC) and
administered in a dose of 100 mg/kg of body weight. These
doses were selected based on previous studies conducted on
these compounds (Kishore et al., 2009). The standard drug
metformin was also prepared similarly as a suspension in
CMC and administered in a dose of 200 mg/kg body weight.
The pre-diabetic control group and normal control group
received only 0.3% CMC suspension. All the treatments were
given once daily orally for 45 days, during which period the
animals were maintained on their respective diets. On day
46, an oral glucose tolerance test (OGTT) was performed
on all the mice and the animals were anesthetized and
blood withdrawn by retro-orbital puncture. Plasma levels of
triglycerides, total cholesterol, HDL cholesterol were estimated
colourimetrically using Star 21 semi-automatic analyser (Rapid
Diagnostic Pvt. Ltd, New Delhi, India) and the levels of AST,
ALT, albumin, creatinine and urea was estimated on Cobas R©
C 111 analyzer (Roche Diagnostics, Basel, Switzerland). The
animals were then sacrificed under excess anesthesia, and
the liver and kidneys collected in 10% formalin, sectioned
and stained using H&E stain (hematoxylin and eosin). The
histopathological assessment was done by an investigator blinded
to the treatment.
Oral Glucose Tolerance Test (OGTT)
Oral glucose tolerance test was performed on mice fasted for 6 h
(Andrikopoulos et al., 2008). Glucose levels of blood taken from
the tip of tail were estimated using a glucometer (Accu-Chek R©
Sensor Comfort, Roche Diagnostics India Pvt. Ltd, Mumbai,
Maharashtra, India) to obtain the basal glucose levels. Then,
glucose (2 g/kg, b.w.) was administered orally and blood glucose
levels were again measured at 5, 15, 30, 60, and 120 min of
glucose administration. Drugs were administered orally 1 h
before glucose administration.
Cell Culture and Maintenance
L6 myoblasts (rat muscles) and RAW264.7 (mouse monocyte
macrophage) cells were procured from National Centre for
Cell Sciences, Pune, Maharashtra, India and maintained in
cell culture flasks (25 or 75 cm2) containing Dulbecco’s
modified Eagle’s medium (DMEM) complete culture medium
(90% DMEM and 10% fetal bovine serum) with 1% penicillin-
streptomycin at 37◦C in a 5% carbon dioxide atmosphere
(CO2 incubator, NU-5510E, NuAire Inc., Plymouth, MN, USA).
After becoming confluent, the cells were trypsinized and
sub-cultured into fresh flasks. For all studies, cells between
passages 15 and 20 were used. L6 myotubes were obtained
by differentiation of myoblasts by modification of method
explained elsewhere (Mitsumoto and Klip, 1992). All the
treatments were done using test compounds solubilized in 0.1%
DMSO.
MTT Assay
Briefly, 100 µl of cell suspension containing 5 × 103 cells
(L6 or RAW264.7) was added in each well of a sterile 96-
well flat bottom tissue culture plate. Twenty four hours later,
cells were treated with different concentrations (25–200 µM)
of test compounds and incubated for 48 h. The control group
was treated only with medium containing 0.1% DMSO. Then,
30 µl of MTT (3-(4,5-dimethyl-2-thiazoyl)-2,5-diphenyl-2H-
tetrazolium bromide) reagent (4 mg/ml) was added in each well
and incubated at room temperature for 4 h. Later, the medium
was removed and 100 µl of DMSO was added to each well and
absorbance was measured using a microplate reader (ELx800,
Biotek Instrument Inc., Winooski, VT, USA) at 540 nm and
IC50 values of the compounds were determined (Mosmann,
1983).
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Estimation of ROS and NO, and Nuclear
Levels of NF-κB in LPS Stimulated RAW
264.7 Macrophages
Previously reported method was used for ROS and NO
estimation (Mathew et al., 2013). Briefly, cell suspension (100 µl),
containing 5 × 104 RAW264.7 cells was seeded in a 96-well
black plate. Twenty four hours later, different concentrations of
standard, L-NAME hydrochloride (NG-nitro-L-arginine methyl
ester) and DPI (diphenylene iodonium) for NO and ROS,
respectively, and test drugs were added to the wells. One hour
after drug addition, 100 µl of LPS (10 µg/ml) was added into
each of the wells and incubated for 20 h. The supernatant was
aspirated from each well and used for nitrite assay. Then to each
of the wells, 100 µM of DCFH-DA (dichloro-dihydro-fluorescein
diacetate) was added and incubated for 1 h, washed with freshly
prepared Hank’s balanced salt solution and fluorescence intensity
measured using a fluorescence microplate reader (FLx800, Biotek
Instrument Inc., Winooski, VT, USA) at λex: 485 nm and λem:
530 nm. For nitrite estimation, 100 µl of freshly prepared Griess
reagent was added to the aspirated supernatant, incubated at
room temperature for 10 min and absorbance measured at
540 nm. The experiment was performed in triplicate.
For measuring the levels of NF-κB, 4 × 106 RAW264.7 cells
seeded in 75 cm2 cell culture flasks were treated with 100 µM
of test drugs and stimulated with LPS as mentioned above. After
the cells were washed, the nuclear fraction was prepared using
commercially available nuclear extraction kit (Cayman Chemical
Company, Ann Arbor, MI, USA) and stored at −80◦C until
estimation of NF-κB by Western blot.
Effect of Test Compounds on
Phosphorylation of AMPK, Akt and p38
MAP Kinase in L6 Myotubes
L6 myoblast cells (2 × 106), seeded in 75 cm2 cell culture
flasks, were differentiated into myotubes, as described elsewhere
(Mitsumoto and Klip, 1992; Yap et al., 2007). The media in the
flasks were replaced with glucose-free DMEM and incubated with
two concentrations (10 and 100 µM) of compounds (metformin,
NAT-1 and NAT-2). Four hours later, the cells were washed with
PBS, scraped, lysed, protein content estimated and subsequently
used for Western blot.
Western Blot Analysis
The protein content of the cell lysates/ fractions was determined
using a bicinchoninic acid assay (BCATM protein assay kit,
Thermo Fisher Scientific Inc., Waltham, MA, USA). The lysates
were adjusted to 20–25 µg of protein and was resolved in
10% SDS-polyacrylamide gel and transferred to a polyvinylidene
difluoride (PVDF) membrane. Then the membrane was blocked
for 1 h at room temperature with 5% non-fat milk protein in
Tris buffered saline (TBS) containing 0.1% Tween 20. The blot
was incubated with 1:1000 dilutions of primary antibodies of
interest and the GAPDH antibody (housekeeping standard) over-
night at 4◦C. The blot was then washed and incubated with a
1:1000 dilution of IgG–horseradish peroxidase (HRP) conjugate.
For estimation of NF-κB, amplified Opti-4CN substrate kit
(Bio-Rad Laboratories Inc., Hercules, CA, USA) was used to
visualize the proteins and image captured using a calibrated
densitometer (GS 800, Bio-Rad Laboratories Inc., Hercules, CA,
USA). For estimation of metabolic markers, signal was captured
using SignalFireTM Plus ECL reagent kit (#12630S, Cell Signaling
Technology Inc., Danvers, MA, USA) on a gel documentation
system (G:BOX Chemi XRQ, Syngene, A Division of Synoptics
Ltd, Cambridge, UK). The experiments were performed in
triplicate. Protein band densities were estimated using the
software ImageJ (version 1.46r, NIH, Bethesda, MD, USA).
Statistical Analysis
The values are given as mean + SEM. The oral glucose tolerance
is expressed as area under the curve (AUC) in arbitrary
units. The levels of NF-κB is expressed as the relative band
density (i.e., ratios of band intensities of NF-κB to that of its
respective GAPDH band). The phosphorylation of AMPK, Akt,
and p38 MAP kinase are expressed as the ratio of relative
densities of phosphorylated and non-phosphorylated proteins
with respect to their corresponding housekeeping protein. The
comparison of glucose and TG levels between normal and
HSD diet animals after 15 months of feeding was analyzed by
unpaired t-test. All other results were analyzed by one way
ANOVA followed by Tukey’s post hoc analysis using Prism
fully functional demo version (version 6.01, GraphPad Software
Inc., La Jolla, CA, USA). p < 0.05 was considered statistically
significant.
RESULTS
Effect of 15-month High-Sucrose Diet on
Fasting Blood Glucose and Triglyceride
Levels in Mice
After 15-month HSD, there was a significant increase (p < 0.05)
in the mean fasting blood glucose and triglyceride levels in the
mice fed the diet, compared to normal animals which were fed
standard rodent diet (Figure 2).
Effect of 45 Days of NAT Treatment on
OGTT in HSD Fed Mice
High sucrose diet significantly altered the glucose tolerance
profile in mice (Figure 3). The mean AUC of the HSD control
group was significantly higher than normal diet fed group.
Treatment for 45 days with metformin, NAT-1 and NAT-2
significantly (p < 0.05) reduced the AUC in HSD fed mice
compared to HSD control (Figure 3B).
After the glucose load, in animals fed normal pellet diet, blood
glucose levels came back to the pre-glucose load (basal) values in
1h whereas in HSD fed group, the basal level was not attained
even after 4 h. In the metformin and NAT-1 treated animals, the
basal glucose levels were attained in hr and in the NAT-2 treated
group glucose levels came back to the initial values by 2 h. The
effect of NAT-1 was comparable with that of the standard drug
(Figure 3A).
Frontiers in Pharmacology | www.frontiersin.org 4 October 2016 | Volume 7 | Article 381
fphar-07-00381 October 14, 2016 Time: 15:32 # 5
Mudgal et al. Anti-diabetic Mechanism of Novel Thiazolidin-4-ones
FIGURE 2 | Effect of 15-month high-sucrose diet on (A) fasting blood
glucose; (B) plasma triglyceride levels in mice. All values are expressed as
mean + SEM (n = 6 for normal animals and 21 for HSD fed animals).
∗p < 0.05 compared to normal diet.
FIGURE 3 | Effect of 15-month high sucrose diet (HSD) on OGTT after a
glucose load (2 g/kg, b.w.), where (A) plot of plasma glucose levels (mg/dl)
vs. time interval; (B) area under the curve (AUC; expressed as arbitrary units)
of the glucose tolerance curve. The time taken for the plasma glucose levels
to come back to their pre-glucose-load values were considered for calculation
of AUC. All values are expressed as mean + SEM (n = 5–6). ap < 0.05
compared to normal control; bp < 0.05 compared to HSD control. In OGTT,
after the glucose load in the normal diet fed group, the basal plasma glucose
levels were attained in less than 60 min whereas in HSD fed group, the basal
levels were was not attained even after 4 h. With metformin and NAT-1
treatment, the basal blood glucose was attained in 60 min and in 2 h by
NAT-2 treatment.
Effect of 45 Days of NAT-1 and NAT-2
Treatments on Lipid Parameters in HSD
Fed Mice
There was a significant rise in the triglyceride levels in HSD fed
mice when compared to the normal diet fed animals (Figure 4A).
NAT-1 and NAT-2 treatments produced a significant reduction in
the elevated TG levels in HSD fed animals.
The cholesterol levels did not rise significantly in HSD fed
mice compared to the normal diet fed animals (Figure 4B).
A significant rise in cholesterol levels was observed with NAT-2
treatment compared to normal animals.
Treatment with NAT-1 led to a statistically significant increase
in the HDL cholesterol level compared to HSD fed animals
(Figure 4C).
Effect of 45 Days of NAT-1 and NAT-2
Treatments on Plasma Albumin, AST and
ALT Levels, and Liver Tissue in HSD Fed
Mice
There were no significant differences observed in the mean
plasma levels of albumin, AST and ALT between the normal
control group and HSD control (Figure 5). Similarly, no changes
were observed in any of the treatment groups. In the HSD group,
liver histology showed focal fatty lobules, lymphocytic infiltration
in lobules and focal dilation of sinusoidal spaces whereas in the
treatment groups only fatty lobules were observed. There was no
fibrosis or steatosis or necrosis observed in any of the groups
(Figure 6).
Effect of 45 Days of NAT-1 and NAT-2
Treatments on Plasma Creatinine and
Urea Levels, and Kidney Tissue in HSD
Fed Mice
After 15-month HSD, there was a significant increase in the
mean plasma urea level in the mice fed the diet, compared to
the animals on normal pellet diet. There were no significant
differences in the mean urea levels of any of the treatment
groups and the animals fed normal pellet diet (Figure 7B).
No significant differences in the plasma mean creatinine levels
were observed in any of the treatment groups (Figure 7A).
Histology of kidney in the HSD fed mice showed focal crowding
of glomeruli and lymphocytic infiltration. Whereas, in all
treatment groups only lymphocytic infiltration was observed
(Figure 8).
Intrinsic Toxicity of the Test Compounds
in Cell Lines
To assess the effect of the test molecules on the activation
of the components of metabolic signaling, we first evaluated
the intrinsic toxicity of the molecules by MTT assay in
L6 and RAW264.7 cells. NAT-1 and NAT-2 were found
to elicit low level cytotoxicity as observed by the IC50
values (µM) of 1654.62 ± 158.77 and 684.18 ± 114.27
in L6 cells and 1436.62 ± 132.62 and 751.25 ± 74.23
in RAW264.7 cells, respectively (data not shown). Based
on the results, it was decided to carry out all in vitro
studies using two doses (100 and 200 µM) of the test
compounds.
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FIGURE 4 | Effect of NAT-1 and NAT-2 on lipid parameters in plasma of HSD-fed mice. (A) Triglyceride levels; (B) total cholesterol levels; (C) HDL cholesterol
levels. All values are expressed as mean ± SEM (n = 5–6). ap < 0.05 vs. normal control, bp < 0.05 vs. HSD control.
FIGURE 5 | Effect of NAT-1 and NAT-2 on liver parameters in plasma of HSD-fed mice. (A) Albumin levels; (B) aspartate aminotransferase (AST) levels;
(C) alanine transaminase (ALT) levels. All values are expressed as mean ± SEM (n = 5–6). No significant difference was observed.
FIGURE 6 | Effect of NAT-1 and NAT-2 on morphological feature of mice liver. Optical microscopy: H&E (200×). Photomicrographs of representative mice are
shown. (A) Normal control; (B) HSD fed control; (C) HSD fed mice treated with metformin; (D) HSD fed mice treated with NAT-1; (E) HSD fed mice treated with
NAT-2.
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FIGURE 7 | Effect of NAT-1 and NAT-2 on kidney parameters in plasma of HSD-fed mice. (A) Creatinine levels; (B) urea levels. All values are expressed as
mean ± SEM (n = 5–6). ap < 0.05 vs. normal control.
FIGURE 8 | Effect of NAT-1 and NAT-2 on morphological feature of mice kidney. Optical microscopy: H&E (200×). Photomicrographs of representative mice
are shown. (A) Normal control; (B) HSD fed control; (C) HSD fed mice treated with metformin; (D) HSD fed mice treated with NAT-1; (E) HSD fed mice treated with
NAT-2.
Effect of NAT-1 and NAT-2 on NO and
ROS Generation, and Levels of NF-κB in
LPS Stimulated RAW264.7 Cells
The compounds were found to have very little effect on the
inhibition of ROS and NO production, and reduction of NF-κB
level in LPS-stimulated RAW264.7 cells. L-NAME hydrochloride,
a NO synthase inhibitor, gave an IC50 value of 156.28± 2.03 µM
whereas in both the test molecules the IC50 values were more than
600 µM (highest concentration tested) in NO inhibition assay
(data not shown). Similarly, DPI, an NAD(P)H oxidase inhibitor,
inhibited ROS production with an IC50 of 4.29 ± 3.53 µM
but both the test molecules were unable to inhibit this with an
IC50 > 600 µM (highest concentration tested) (data not shown).
Also, LPS treatment significantly increased the levels of NF-κB
levels in the nuclear fraction of LPS stimulated RAW 264.7 cells
compared to untreated (normal) control. The molecules, NAT-1
and NAT-2 were found to be ineffective in reducing the levels of
NF-κB in RAW264.7 cells stimulated with LPS when compared
to LPS treated control group (Figure 9).
Effect of NAT-1 and NAT-2 on
Phosphorylation of AMPK, Akt, and p38
MAP Kinase in L6 Cells
Immunoblotting results from metformin (100 µM) pre-treated
L6 myotubes revealed that the standard drug significantly
increased phosphorylation of AMPK (at Th172) and p38 MAP
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FIGURE 9 | Effect of NAT-1 and NAT-2 on nuclear levels of NF-κB in LPS stimulated RAW264.7 cells where (A) blot showing nuclear levels of NF-κB;
(B) relative density ratio of NF-κB/GAPDH. Values are expressed as mean ± SEM. ap < 0.05 vs. normal control.
FIGURE 10 | Effect of NAT-1 and NAT-2 on phosphorylation of molecular markers – AMPK, p38 MAP kinase and Akt in L6 cells, where (A) representative
blots showing the levels of various markers and their phosphorylated forms tested; (B) ratio of relative densities of phospho-AMPK and AMPK; (C) ratio of relative
densities of phospho-p38 MAPK and p38 MAPK; (D) ratio of relative densities of phospho-Akt and Akt. RD represents ratio of band intensity of marker protein to its
respective housekeeping protein, i.e., GAPDH. Values are expressed as mean ± SEM. ap < 0.05 vs. normal control.
kinase when compared to the respective untreated controls
(Figures 10A–C).
Treatment with NAT-1 and NAT-2 (both 10 and 100 µM
doses) did not increase the levels of phosphorylated AMPK, as
compared to the control (Figure 10B).
However, NAT-1 and NAT-2 at 100 µM showed a significant
increase in phosphorylated Akt and p38 MAP kinase levels
(Figures 10C,D).
DISCUSSION
Previously, we had demonstrated the antidiabetic potential of
NAT-1 and NAT-2 in STZ-induced diabetic mice (Kishore
et al., 2009). However, the model of hyperglycaemia induced
by injection of STZ has several limitations, viz. progression
of mild hyperglycaemia into frank Type I diabetic condition,
spontaneous recovery of animals, poor resemblance of the model
with human Type II diabetes etc. STZ may be more suitable for
developing a rodent model resembling human Type I diabetes,
screening newer formulations of insulin, beta cell transplantation
studies, and for treatments that may prevent beta cell death (King,
2012). In this regard, experiments were conducted to assess the
antidiabetic activity of NAT-1 and NAT-2 in a diet induced
pre-diabetic model in mice.
Metabolic effects of chronic high carbohydrate diet manifest
as weight gain, glucose intolerance, insulin resistance, and
hypertrophy and hyperplasia of β-cells (Ramirez et al., 1990). But
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frank hyperglycaemia is usually not observed. Our attempts in
developing a model of diabetes by feeding HSD (30–60% sucrose)
over a period of 3, 6, 9, 12, and 15 months in Swiss albino
mice yielded a consistent pre-diabetic condition in those animals
which were fed HSD (55% sucrose) for 15 months. In the present
study, a high carbohydrate diet containing higher proportions
of sucrose resulted in increased weight gain, glucose intolerance,
impaired lipid profile and frank hyperglycaemia which may be
the result of maintaining the animals for a longer period on HSD.
Treatment with NAT-1 and NAT-2 reduced the glucose
intolerance as is evident from the AUC of the OGTT curve,
the activity of NAT-1 being comparable to that of the standard
drug metformin. The molecules also significantly reduced the
elevated plasma triglyceride levels but elevated total cholesterol
levels. However, a significant rise in the HDL cholesterol levels
with NAT-1 was observed and we assume that the rise in total
cholesterol levels could have been in part due to the increase in
HDL levels. The rise in total cholesterol with NAT-2 is consistent
with previous reports but a satisfactory explanation cannot be
given at this stage. The structures of both NAT-1 and NAT-2
possess nicotinamide moiety which could have contributed to
the rise in HDL cholesterol but further pharmacokinetic studies
on the metabolism of the molecules are needed to confirm
this. Despite treatment with NAT-1 and NAT-2 for a period of
45 days, the biochemical profile of the liver and kidney markers
were largely unaffected. This was additionally confirmed as no
major histological changes were present in liver and kidney
tissues.
In the previous studies, the compounds NAT-1 and NAT-
2 had shown increased glucose uptake and caused beta cell
regeneration in an STZ model (Kishore et al., 2009). Further,
NAT-1 exhibited a dose-response effect on hyperglycaemia (Karot
et al., 2015). Therefore, to explore the underlying mechanism,
in vitro experiments were designed in L6 myotubes on AMPK,
Akt and p38 MAP kinase pathways.
In the studies on L6 myotubes, we have demonstrated a
rise in phosphorylated AMPK levels with metformin which
is in line with published reports. Also, the drug was found
to increase the phosphorylation of p38 MAP kinase. Both the
test molecules, NAT-1 and NAT-2 at 100 µM significantly
increased the phosphorylation of Akt and MAP kinase
(Figure 10). This indicates a possible activation of the PI3/Akt
pathway which could have partly contributed to their anti-
hyperglycaemic activity in vivo. It cannot be confirmed whether
the phosphorylation of Akt by the test molecules is due to any
direct action on Akt or by some indirect action that leads to
phosphorylation of Akt. Further studies are required to confirm
this.
Clinically used thiazolidine-2,4-diones, acting through PPAR-
gamma receptor activation, play a vital role in pancreatic beta
cell protection and preserves the islets from apoptosis (Kanda
et al., 2010). The mechanisms involved in the protective effect
by thiazolidine-2,4-diones also involve inhibition of cytokine
production through NF-κB signaling (Remels et al., 2009). In the
present study, the investigational thiazolidinon-4-one derivatives
(NAT-1 and NAT-2) failed to inhibit the generation of ROS
and nitrite, and increased the nuclear levels of NF-κB in LPS
stimulated RAW 264.7 cells. Therefore, the previously reported
pancreas protection by these molecules could not have been due
to any anti-inflammatory properties. However, the test molecules
activated p38 MAP kinase, a regulator of gene expression and
cell survival. This could have contributed to the β cell protection
(Kishore et al., 2009).
In summary, the anti-hyperglycaemic and hypolipidemic
molecules, NAT-1 and NAT-2, could not activate AMPK. Both the
molecules were able to phosphorylate Akt and p38 MAP kinase
which could partially be responsible for their pharmacological
actions.
Both the molecules have a thiazolidin-4-one moiety in
their structure, a possible action on peroxisome proliferator
activated receptor-gamma (PPAR-γ), a transcription factor
activated by thiazolidinedione category of anti-diabetic drugs
like pioglitazone, should be assessed by evaluating the target
gene products of PPAR-γ. Also, the nicotinic acid moiety in
the structure extends the possibility that the molecules could
be interacting with members of nicotinic acid receptor family.
Research on such lines could also be undertaken in future.
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